Meta-analysis of Efficacy and Safety of Single or Dual Antiplatelet Therapy for Short-term Complications after Transcatheter Aortic Valve Implantation / 中国药房
China Pharmacy
; (12): 1271-1278, 2019.
Article
in Zh
| WPRIM
| ID: wpr-816977
Responsible library:
WPRO
ABSTRACT
OBJECTIVE: To systematically evaluate effectiveness and safety of single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) on short-term complications after transcatheter aortic valve implantation (TAVI), and to provide evidence-based reference for clinical treatment. METHODS: Retrieved from PubMed, Cochrane clinical controlled trials registry, Web of Science, CNKI, Wanfang database, CBM and Chinese Clinical Trial Registry, RCTs and observational studies about effectiveness (all-cause mortality, incidence of stroke and incidence of myocardial infarction 30 days after operation) and safety (the incidence of bleeding events at 30 days after operation) of SAPT versus DAPT on short-term complications of TAVI were collected during the date of database establishment to Jan. 2019. After data extraction of included studies and quality evaluation with Cochrane system evaluator manual 5.1.0 (for RCT) and the Newcastle-Ottawa Scale (NOS) (for observational studies), Meta-analysis was conducted by using Rev Man 5.3 statistical software. RESULTS: Totally 3 RCTs and 7 cohort studies were included, involving 3 188 patients. Results of Meta-analysis showed that the incidence of all-cause mortality 30 days after operation [OR=0.48, 95% CI (0.32, 0.73), P<0.001] and the incidence of bleeding events 30 days after operation [OR=0.43, 95%CI (0.30, 0.59), P<0.001] in SAPT group were significantly lower than DAPT group, with statistical significance. There was no statistical significance in the incidence of stroke 30 days after operation [OR=0.63, 95%CI (0.38, 1.06) , P=0.08] or the incidence of myocardial infarction 30 days after operation [OR=1.09, 95%CI (0.46, 2.59), P=0.85] between 2 groups. CONCLUSIONS: Compared with DAPT, SAPT can decrease the incidence of all-cause mortality 30 days after TAVI and the incidence of bleeding events 30 days after TAVI.
Full text:
1
Index:
WPRIM
Type of study:
Clinical_trials
/
Guideline
/
Observational_studies
/
Systematic_reviews
Language:
Zh
Journal:
China Pharmacy
Year:
2019
Type:
Article